These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35441304)

  • 1. ASO Author Reflections: The Need for Improvement of the 8th American Joint Committee on Cancer TNM Staging System for Resected Pancreatic Ductal Adenocarcinoma.
    Schouten TJ; Daamen LA; van Santvoort HC; Molenaar IQ
    Ann Surg Oncol; 2022 Sep; 29(9):6000-6001. PubMed ID: 35441304
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma.
    Shin DW; Lee JC; Kim J; Woo SM; Lee WJ; Han SS; Park SJ; Choi KS; Cha HS; Yoon YS; Han HS; Hong EK; Hwang JH
    Eur J Surg Oncol; 2019 Nov; 45(11):2159-2165. PubMed ID: 31202572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma.
    Pu N; Yin L; Habib JR; Gao S; Hu H; Zhu Y; Wu Y; Yu J; Lou W
    Future Oncol; 2019 Oct; 15(30):3457-3465. PubMed ID: 31460788
    [No Abstract]   [Full Text] [Related]  

  • 4. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
    van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
    JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.
    Chen YT; Huang ZP; Zhou ZW; He MM
    Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASO Author Reflections: Prognostic Value of Tumor Deposits in Resected Pancreatic Ductal Adenocarcinoma.
    Hua J; Shi S
    Ann Surg Oncol; 2023 May; 30(5):3045. PubMed ID: 36695995
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma.
    Malleo G; Maggino L; Fernàndez-Del Castillo C; Salvia R
    Ann Surg Oncol; 2020 Oct; 27(10):3913-3914. PubMed ID: 32399766
    [No Abstract]   [Full Text] [Related]  

  • 8. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade.
    König AK; Gros H; Hinz U; Hank T; Kaiser J; Hackert T; Bergmann F; Büchler MW; Strobel O
    Eur J Surg Oncol; 2022 Jan; 48(1):113-120. PubMed ID: 34344573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer.
    Schouten TJ; Daamen LA; Dorland G; van Roessel SR; Groot VP; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven M; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verdonk RC; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
    Ann Surg Oncol; 2022 Sep; 29(9):5988-5999. PubMed ID: 35469113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
    Groot VP; Wolfgang CL; He J
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
    [No Abstract]   [Full Text] [Related]  

  • 11. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
    Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
    Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level.
    Sumiyoshi T; Uemura K
    Ann Surg Oncol; 2024 Jul; 31(7):4697. PubMed ID: 38739237
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: The Challenge of Minimal Residual Disease.
    Belfiori G; Crippa S; Falconi M
    Ann Surg Oncol; 2024 Jun; 31(6):4115-4116. PubMed ID: 38472672
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System.
    Redegalli M; Schiavo Lena M
    Ann Surg Oncol; 2022 Jun; 29(6):3503. PubMed ID: 35187623
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail.
    Kitamura K; Esaki M; Sone M; Sugawara S; Hiraoka N; Nara S; Ban D; Takamoto T; Mizui T; Shimada K
    Ann Surg Oncol; 2022 Oct; 29(11):7059-7060. PubMed ID: 35648319
    [No Abstract]   [Full Text] [Related]  

  • 16. The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study.
    Sheng W; Dong M; Wang G; Shi X; Gao W; Wang K; Song H; Shi G; Tan X
    BMC Cancer; 2019 Oct; 19(1):981. PubMed ID: 31640615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refined TNM-staging for pancreatic adenocarcinoma - Real progress or much ado about nothing?
    Roalsø M; Aunan JR; Søreide K
    Eur J Surg Oncol; 2020 Aug; 46(8):1554-1557. PubMed ID: 32107094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma.
    Schlitter AM; Jesinghaus M; Jäger C; Konukiewitz B; Muckenhuber A; Demir IE; Bahra M; Denkert C; Friess H; Kloeppel G; Ceyhan GO; Weichert W
    Eur J Cancer; 2017 Oct; 84():121-129. PubMed ID: 28802189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASO Author Reflections: Timing of Systemic Therapy and Postoperative Morbidity in Resectable Pancreatic Ductal Adenocarcinoma and Distal Cholangiocarcinoma.
    Macfie R; Cohen N
    Ann Surg Oncol; 2023 Aug; 30(8):5035. PubMed ID: 37179272
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Pancreatic Invasion is a Crucial Independent Prognostic Factor in Duodenal Carcinoma.
    Nitta N; Ohgi K; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Sasaki K; Uesaka K
    Ann Surg Oncol; 2020 Oct; 27(11):4561. PubMed ID: 32462525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.